Data Updates in the Treatment of Resectable Cutaneous Squamous Cell Carcinoma (CSCC) - Episode 11
Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.